Cartesian Therapeutics

Historical price data

Cartesian Therapeutics is a clinical-stage biotechnology company with a mission to expand the reach of cell therapy beyond oncology into autoimmune diseases. The company's core innovation is an mRNA cell therapy platform designed to transiently engineer patient-derived cells to produce therapeutic proteins locally at disease sites, aiming for a favorable safety and efficacy profile. Its strategy is validated by a maturing clinical pipeline, led by Descartes-08 in Phase 2b for generalized myasthenia gravis, positioning it as a public leader in this emerging therapeutic modality. Cartesian faces significant execution risks but operates in a vast and underserved market with a potentially disruptive technology.

Proprietary mRNA cell therapy platform for transient ex vivo engineering of patient-derived immune cells (e.g., T cells, Tregs) to express therapeutic proteins, aiming for targeted delivery with a favorable safety profile.

Competes with chronic biologics (e.g., FcRn inhibitors) and permanent viral-vector CAR-T therapies in autoimmunity. Differentiation hinges on demonstrating a superior safety/efficacy balance via transient expression. Cartesian is a public pure-play leader in the nascent mRNA cell therapy for autoimmunity space.